Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.07 | $364.20 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 8 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,702 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 05, 2019 Filed Aug 16, 2019 21:11 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,500 | $6.08 | $9,120.00 |
DisclosureSEC source: 0001209191-19-046347 · doc4.xml · nonDerivative · entry 3 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,530 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.10 to $6.05, inclusive. Read SEC document |
| August 05, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.17 | $370.20 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 7 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,718 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 05, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.17 | $401.05 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 7 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,207 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 05, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.17 | $370.20 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 7 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,642 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 02, 2019 Filed Aug 16, 2019 21:11 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 400 | $6.07 | $2,428.00 |
DisclosureSEC source: 0001209191-19-046347 · doc4.xml · nonDerivative · entry 2 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,030 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.15 to $6.00, inclusive. Read SEC document |
| August 02, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 120 | $6.15 | $738.00 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,658 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 02, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 130 | $6.15 | $799.50 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 6 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,142 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 02, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 120 | $6.15 | $738.00 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 6 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,582 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 02, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $6.13 | $459.75 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 6 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,004 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 01, 2019 Filed Aug 16, 2019 21:11 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 800 | $5.96 | $4,768.00 |
DisclosureSEC source: 0001209191-19-046347 · doc4.xml · nonDerivative · entry 1 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,430 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.01 to $5.91, inclusive. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 21:19 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,100 | $5.91 | $6,501.00 |
DisclosureSEC source: 0001209191-19-044309 · doc4.xml · nonDerivative · entry 9 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,230 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F11 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.90, inclusive. Read SEC document |
| July 31, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.94 | $356.40 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,538 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 31, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.94 | $386.10 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 5 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,012 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 31, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.94 | $356.40 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 5 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,462 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 30, 2019 Filed Aug 2, 2019 21:19 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 644 | $5.81 | $3,741.64 |
DisclosureSEC source: 0001209191-19-044309 · doc4.xml · nonDerivative · entry 8 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,330 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F10 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.83 to $5.80, inclusive. Read SEC document |
| July 30, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.83 | $349.80 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,478 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 30, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.83 | $378.95 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 4 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,947 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 30, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.83 | $349.80 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 4 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,402 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 30, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.97 | $447.75 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 5 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,929 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 29, 2019 Filed Aug 2, 2019 21:19 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 424 | $5.84 | $2,476.16 |
DisclosureSEC source: 0001209191-19-044309 · doc4.xml · nonDerivative · entry 7 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,974 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F9 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.89 to $5.83, inclusive. Read SEC document |
| July 29, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.87 | $352.20 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,418 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 29, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.87 | $381.55 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 3 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,882 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 29, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.87 | $352.20 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 3 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,342 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 26, 2019 Filed Aug 2, 2019 21:19 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 500 | $5.83 | $2,915.00 |
DisclosureSEC source: 0001209191-19-044309 · doc4.xml · nonDerivative · entry 6 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,398 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F8 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.80, inclusive. Read SEC document |
| July 26, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.86 | $351.60 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,358 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 26, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.86 | $380.90 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 2 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,817 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 26, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.86 | $351.60 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 2 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,282 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 25, 2019 Filed Aug 2, 2019 21:19 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 500 | $5.85 | $2,925.00 |
DisclosureSEC source: 0001209191-19-044309 · doc4.xml · nonDerivative · entry 5 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,898 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F7 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.85, inclusive. Read SEC document |
| July 25, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.87 | $352.20 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,298 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 25, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.87 | $381.55 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 1 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,752 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 25, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.87 | $352.20 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 1 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,222 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 25, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.87 | $440.25 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 4 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,854 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.93 | $355.80 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 28 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,238 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.92 | $384.80 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 28 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,737 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.93 | $355.80 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 28 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,162 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 24, 2019 Filed Aug 2, 2019 21:19 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 900 | $5.84 | $5,256.00 |
DisclosureSEC source: 0001209191-19-044309 · doc4.xml · nonDerivative · entry 4 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,398 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F6 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.89 to $5.76, inclusive. Read SEC document |
| July 22, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.75 | $345.00 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 27 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,178 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 22, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.75 | $373.75 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 27 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,672 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 22, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.75 | $345.00 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 27 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,102 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 22, 2019 Filed Aug 2, 2019 21:19 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 200 | $5.63 | $1,126.00 |
DisclosureSEC source: 0001209191-19-044309 · doc4.xml · nonDerivative · entry 3 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,298 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.64 to $5.62, inclusive. Read SEC document |
| July 19, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.69 | $341.40 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 26 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,118 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 19, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.69 | $369.85 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 26 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,607 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 19, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.69 | $341.40 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 26 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,042 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 19, 2019 Filed Aug 2, 2019 21:19 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 104 | $5.61 | $583.44 |
DisclosureSEC source: 0001209191-19-044309 · doc4.xml · nonDerivative · entry 2 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,498 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.61 to $5.62, inclusive. Read SEC document |
| July 19, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.69 | $426.75 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 3 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,779 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 18, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.84 | $350.40 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 25 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,058 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 18, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.83 | $378.95 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 25 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,542 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 18, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.84 | $350.40 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 25 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,982 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 18, 2019 Filed Aug 2, 2019 21:19 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 500 | $5.69 | $2,845.00 |
DisclosureSEC source: 0001209191-19-044309 · doc4.xml · nonDerivative · entry 1 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,602 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.69 to $5.69, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.